Referências

1. Blair HA. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2021;81(4):483-494. 2. Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D’Angelo S, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis.2021;80(5):582-90. 3. Mease P, van der Heijde D, Landewé R, Mpofu S, Rahman P, Tahir H, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890-897. 4. Deodhar A, Blanco R, Dokoupilová E, Hall S, Kameda H, Kivitz AJ, et al. Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study. Arthritis Rheumatol. 2021;73(1):110-120. 5. Reich K, Sullivan J, Arenbergeret P, Jazayeri S, Mrowietz U, Augustin M, et al. Secukinumab shows significant efficacy in nail psoriasis: week 32 results from the Transfigure study. Ann Rheum Dis. 2016;75-S2:603-4. 6. Sotiriou E, Bakirtzi K, Vakirlis E, Papadimitriou I, Eftychidou P, Trifona M, et al. Long-term drug survival of secukinumab in real life in the era of novel biologics: a 5-year, retrospective study, including difficult-to-treat areas. J Eur Acad Dermatol Venereol. 2022;36(8):e626-7. 7. Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, et al.; FUTURE 1 study group. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatol. 2020;2(1):18-25. 8. McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020;395(10235):1496-505. 9. Coates LC, Soriano E, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-79. 10. Carneiro S, Palominos PE, Anti SMA, Assad RL, Gonçalves RSG, Chiereghin A, et al. Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis. Adv Rheumatol. 2021;61(1):69.